User login
Key clinical point: Treatment intensification with 300 units/mL insulin glargine (Gla-300) in patients with type 2 diabetes mellitus (T2D) receiving glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly improved glycemic control without increasing the risk for hypoglycemia.
Major finding: Addition of Gla-300 to GLP-1 RA therapy significantly reduced glycated hemoglobin (HbA1c) level (mean change −0.97% ± 1.6%; P < .0001) and significantly increased the proportion of patients achieving glycemic control (HbA1c <7.0%: change 17.34%; HbA1c <8.0%: change 31.73%; both P < .001), with no significant changes in overall incidence or event rate of hypoglycemia.
Study details: The data come from a retrospective analysis of 271 insulin-naive patients with T2D receiving GLP-1 RA who underwent treatment intensification with Gla-300.
Disclosures: This study was funded by Sanofi. TS Bailey declared receiving research support and consulting and speaking honoraria from various sources, including Sanofi. C Nicholls, J Gill, and J Westerbacka declared being employees and stockholders of Sanofi.
Source: Bailey TS et al. Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to GLP-1 RA therapy in people with type 2 diabetes: The DELIVER-G study. Diabetes Obes Metab. 2022 (May 1). Doi: 10.1111/dom.14739
Key clinical point: Treatment intensification with 300 units/mL insulin glargine (Gla-300) in patients with type 2 diabetes mellitus (T2D) receiving glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly improved glycemic control without increasing the risk for hypoglycemia.
Major finding: Addition of Gla-300 to GLP-1 RA therapy significantly reduced glycated hemoglobin (HbA1c) level (mean change −0.97% ± 1.6%; P < .0001) and significantly increased the proportion of patients achieving glycemic control (HbA1c <7.0%: change 17.34%; HbA1c <8.0%: change 31.73%; both P < .001), with no significant changes in overall incidence or event rate of hypoglycemia.
Study details: The data come from a retrospective analysis of 271 insulin-naive patients with T2D receiving GLP-1 RA who underwent treatment intensification with Gla-300.
Disclosures: This study was funded by Sanofi. TS Bailey declared receiving research support and consulting and speaking honoraria from various sources, including Sanofi. C Nicholls, J Gill, and J Westerbacka declared being employees and stockholders of Sanofi.
Source: Bailey TS et al. Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to GLP-1 RA therapy in people with type 2 diabetes: The DELIVER-G study. Diabetes Obes Metab. 2022 (May 1). Doi: 10.1111/dom.14739
Key clinical point: Treatment intensification with 300 units/mL insulin glargine (Gla-300) in patients with type 2 diabetes mellitus (T2D) receiving glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly improved glycemic control without increasing the risk for hypoglycemia.
Major finding: Addition of Gla-300 to GLP-1 RA therapy significantly reduced glycated hemoglobin (HbA1c) level (mean change −0.97% ± 1.6%; P < .0001) and significantly increased the proportion of patients achieving glycemic control (HbA1c <7.0%: change 17.34%; HbA1c <8.0%: change 31.73%; both P < .001), with no significant changes in overall incidence or event rate of hypoglycemia.
Study details: The data come from a retrospective analysis of 271 insulin-naive patients with T2D receiving GLP-1 RA who underwent treatment intensification with Gla-300.
Disclosures: This study was funded by Sanofi. TS Bailey declared receiving research support and consulting and speaking honoraria from various sources, including Sanofi. C Nicholls, J Gill, and J Westerbacka declared being employees and stockholders of Sanofi.
Source: Bailey TS et al. Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to GLP-1 RA therapy in people with type 2 diabetes: The DELIVER-G study. Diabetes Obes Metab. 2022 (May 1). Doi: 10.1111/dom.14739